Klin Farmakol Farm. 2004;18(3):171-174

Nežádoucí účinky amiodaronu

Bogna Jiravská Godula1, Pavel Vávra1, Otakar Jiravský2, Marian Branny2
1 Interní oddělení NsP Havířov
2 Kardiocentrum Nemocnice Podlesí, Třinec

Keywords: amiodarone, adverse effects.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jiravská Godula B, Vávra P, Jiravský O, Branny M. Nežádoucí účinky amiodaronu. Klin Farmakol Farm. 2004;18(3):171-174.

Amiodaron je lékem užívaným v lékařské praxi již od roku 1962. Jeho účinky jsou dostatečně prozkoumány. Stejně tak jsou velmi dobře známy i jeho nežádoucí účinky.

Ve světě i v ČR dochází k postupnému narůstání užívání tohoto léku. Spolu s narůstajícím počtem pacientů a spolu s narůstající délkou jejich léčby se zvyšuje počet zaznamenaných nežádoucích účinků.

Tento článek podává jejich přehled, snaží se přiblížit mechanizmy vzniku nežádoucích účinků a předkládá postupy k jejich zvládnutí. Autoři zde diskutují nutnost vysazení amiodaronu a nebo možnost pokračování v terapii při jednotlivých typech nežádoucích účinků.

THE ADVERSE EFFECTS OF AMIODARONE

Amiodarone is an antiarrythmic agent commonly used in the treatment of supraventricular and ventricular tachyarrhytmias. It was registered by FDA in 1962. The effects of these drug are well known. The adverse effects are well known in the same way.

The usage of amiodarone has gradually increased in the Czech Republic and in the world. The adverse effects has increased much the same as number of treated pacients.

The authors present summary of all adverse effects, show mechanisms of their origin and discuss possibility of continuation of amiodarone therapy and the neccesity of discontinuation

Download citation

References

  1. Iudica-Souza C, Burch HB. Amiodarone - induced thyroid dysfunction, The Endocrinologist, 1999; 9: 216-227. Go to original source...
  2. Stuart J. Connoly: Evidence Based Analysis of Amiodarone Efficacy and Safety, Circulation, 1999; 100: 2025-2034. Go to original source... Go to PubMed...
  3. Katzung BG. Základní & klinická farmakologie, H&H, 1994, 211 s.
  4. Roden DM. Pharmacokinetics of Amiodarone: Implications for Drug Therapy, Am J Cardiol, 1993; 72: 45-50. Go to original source... Go to PubMed...
  5. Kowey P, Marinchak R, Rials S, Filart R. Intravenous Amiodarone, J Am Coll Cardiol, 1997; 29: 1190-1198. Go to original source... Go to PubMed...
  6. Braunwald E. Heart disease. A Textbook of Cardiovascular Medicine, Saunders comp, 1997, 614 s.
  7. Greene L, Graham L, Werner A, Sears K, GrossW, Gorham P. Toxic and therapeutic effects of amiodarone in threatment of cardiac arrythmias, J Am Coll Cardiol,1983; 2: 1114-1128. Go to original source... Go to PubMed...
  8. Manson JW. Amiodarone, N Engl J Med, 1987; 316: 455-466. Go to original source... Go to PubMed...
  9. Jafari-Fesharaki M. Adverse Effects of Amiodarone, Pace, 1998; 21: 108-120. Go to original source... Go to PubMed...
  10. http://www.medscape.com/druginfo/
  11. Wilson JS, Podrig JP. Side effect of amiodarone, Am Heart J, 1991; 121: 158-171. Go to original source... Go to PubMed...
  12. Polkey MI, Wilson POG, Ress PJ. Amiodarone pneumonitis: No safe dose, Respiratory Medicine, 1995; 89: 233-235. Go to original source... Go to PubMed...
  13. Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity: Recognition and pathogenesis, Chest, 1998; 93: 1067-1075. Go to original source... Go to PubMed...
  14. Ingram DV. Ocular effects in long term amiodarone therapy, Am Heart J, 1983; 106: 902-904. Go to original source... Go to PubMed...
  15. Raeder AE, Podrid JP, Lown B. Side effects and complications of amiodarone therapy, Am Heart J, 1985, 109: 975-983. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.